HRP20080608T3 - Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze - Google Patents

Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze

Info

Publication number
HRP20080608T3
HRP20080608T3 HR20080608T HRP20080608T HRP20080608T3 HR P20080608 T3 HRP20080608 T3 HR P20080608T3 HR 20080608 T HR20080608 T HR 20080608T HR P20080608 T HRP20080608 T HR P20080608T HR P20080608 T3 HRP20080608 T3 HR P20080608T3
Authority
HR
Croatia
Prior art keywords
independently selected
optionally substituted
halogen
alkyl
co2h
Prior art date
Application number
HR20080608T
Other languages
English (en)
Inventor
Paul Mathias John
Simon Millan David
Andrew Lewthwaite Russell
Phillips Christopher
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0418015A external-priority patent/GB0418015D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20080608T3 publication Critical patent/HRP20080608T3/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)

Abstract

Spoj formule (I), ili njegova farmaceutski prihvatljiva sol i/ili solvat (uključujući hidrat); ,gdjeR1 je CH3, SCH3, SCH2CH3, CH2CH3, H ili CH2SCH3; R1a je CH3 ili CH2CH3;R2 je heteroaril, heterociklil, aril ili karbociklil; R3 je heteroaril, heterociklil, aril, karbociklil ili R7;R7 je (C1-C6)alkil izborno supstituirani s jednim ili više supstituenata, koje se neovisno bira između OH, halogena, NR5R6, (C1-C8)alkoksi, -S(O)p(C1-C8)alkila, CO2H, CONR5R6, heteroarila, heterociklila, arila, karbociklila, ariloksi, karbocikliloksi, heteroariloksi,te heterocikliloksi; p je 0, 1 ili 2; svakog od R5 i R6 se neovisno bira između H i (C1-C4)alkila, gdje je navedeni (C1-C4)alkil izborno supstitiran s jednim ili više supstituenata, koje se neovisno bira između OH i halogena, ili R5 i R6, zajedno s dušikom, na kojeg su vezani, tvore piperazinilnu, piperidinilnu, morfolinilnu ili pirolidinilna skupinu, gdje je svaki od navedenih piperazinila, piperidinila, morfolinila i pirolidinila izborno supstituiran s jednim ili više OH; "aril" znači fenil ili naftil, gdje su navedeni fenil ili naftil izborno supstituirani s jednim ili više supstituenata, koje se neovisno bira između halogena, -CN, -CO2H,ON, CONR5R6, R7, te R8;R8 se bira između (C1-C6)alkila, (C1-C6)alkoksi, -CO2(C1-C6)alkila, -S(O)p(C1-C6)alkila, -CO(C1-C6) alkila, te (C3-C7)cikloalkila; svaki R5 je izborno supstituiran s jednim iliviše supstituenata, koje se neovisno bira između:(C1-C6)alkoksi, izborno supstituiranog s jednim ili više supstituenata, koje se neovisno bira između OH, halogena, CO2H, CONR5R6, te NR5R6,-S(O)p(C1-C6)alkila, izborno supstituiranog s jednim ili više supstituenata, koje se neovisno bira između OH, halogena, CO2H, CONR5R6, te NR5R6,OH, halogena, NR5R6,CO2H, CONR5R6, teR9;R9 je heteroaril2, heterociklil2, aril2, karbociklil2, aril2oksi, karbociklil2oksi, heteroaril2oksi ili heterociklil2oksi; "aril2" znači fenil ili naftil, gdje su navedeni fenil ili naftil izborno supstituirani s jednim ili više supstituenata, koje se neovisno bira između halogena, -CN, CO2H, OH, te CONR5R6;"karbociklil" znači mono- ili biciklički, zasićeni ili djelomično nezasićeni prstenasti sustav, koji sadrži 3 do 10 atoma ugljika u prstenu, izborno supstituiran s jednim ili više supstituenata, koje se neovisno bira između halogena, -CN, -CO2H, OH, CONR5R6, R8, te R9;"karbociklil2" znači mono- ili biciklički, zasićeni ili djelomično nezasićeni prstenasti sustav, koji sadrži 3 do 10 atoma ugljika u prstenu, izborno supstituiran s jednim ili više supstituenata, koje se neovisno bira između halogena, -CN, -CO2H, OH, te CONR5R6;svaki "heterociklil", i "heterociklil2" neovisno znači 3- do 10- člana, zasićena ili djelomično nezasićena, mono- ili biciklička skupina, koja sadrži 1 do 4 heteroatoma u prstenu, koje se neovisno bira između N, O, te S; svaki "heteroaril", te svaki "heteroaril2", neovisno znači 5- do 10- člana, mono- ili biciklička, aromatska skupina, koja sadrži 1 do 4 heteroatoma u prstenu, koje se neo
HR20080608T 2004-08-12 2008-11-24 Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze HRP20080608T3 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0418015A GB0418015D0 (en) 2004-08-12 2004-08-12 New compounds
US69155905P 2005-06-17 2005-06-17
PCT/IB2005/002574 WO2006018718A2 (en) 2004-08-12 2005-08-09 Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20080608T3 true HRP20080608T3 (hr) 2008-12-31

Family

ID=35783420

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080608T HRP20080608T3 (hr) 2004-08-12 2008-11-24 Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze

Country Status (35)

Country Link
US (2) US7511057B2 (hr)
EP (1) EP1778686B9 (hr)
JP (1) JP4084836B2 (hr)
AP (1) AP2326A (hr)
AR (1) AR050692A1 (hr)
AT (1) ATE412652T1 (hr)
AU (1) AU2005273612B2 (hr)
BR (1) BRPI0514255A (hr)
CA (1) CA2576297C (hr)
CR (1) CR8918A (hr)
CU (1) CU23497A3 (hr)
CY (1) CY1108788T1 (hr)
DE (1) DE602005010714D1 (hr)
DK (1) DK1778686T3 (hr)
EA (1) EA012119B1 (hr)
EC (1) ECSP077232A (hr)
ES (1) ES2314690T3 (hr)
GE (1) GEP20104973B (hr)
GT (1) GT200500218A (hr)
HK (1) HK1105536A1 (hr)
HN (1) HN2005000418A (hr)
HR (1) HRP20080608T3 (hr)
IL (1) IL181047A (hr)
MA (1) MA28798B1 (hr)
MX (1) MX2007001759A (hr)
MY (1) MY140021A (hr)
NL (1) NL1029726C2 (hr)
NO (1) NO339320B1 (hr)
NZ (1) NZ552868A (hr)
PL (1) PL1778686T3 (hr)
PT (1) PT1778686E (hr)
SI (1) SI1778686T1 (hr)
SV (1) SV2006002193A (hr)
TN (1) TNSN07050A1 (hr)
WO (1) WO2006018718A2 (hr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20090012079A1 (en) * 2006-02-09 2009-01-08 Russell Andrew Lewthwaite Triazolopyridine Compounds
JP5244369B2 (ja) * 2006-11-10 2013-07-24 富士フイルム株式会社 ５−アミノピラゾール誘導体の製造方法、アゾ色素
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
MX2010008535A (es) * 2008-02-04 2010-08-30 Pfizer Ltd Forma polimorfa de un derivado de [1,2,4] triazolo [4,3-a] piridina para tratamiento de enfermedades inflamatorias.
US8498729B2 (en) 2008-08-29 2013-07-30 Smp Logic Systems Llc Manufacturing execution system for use in manufacturing baby formula
US20110166059A1 (en) * 2008-09-12 2011-07-07 Dorothee Viemann Means and methods for evaluating a therapy with a p38 map kinase inhibitor
BRPI1005327A2 (pt) 2009-02-17 2019-09-24 Chiesi Farm Spa derivados de triazolopiridina como inibidores de p38 map quinase
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
TWI500614B (zh) 2009-06-05 2015-09-21 Cephalon Inc １，２，４－三唑並〔１，５ａ〕吡啶衍生物之製備和用途
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
EP2556068B1 (en) 2010-04-08 2019-01-23 Respivert Limited P38 map kinase inhibitors
WO2011158044A2 (en) 2010-06-17 2011-12-22 Respivert Limited Respiratory formulations and compounds for use therein
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
BR112014007694B1 (pt) 2011-10-03 2022-09-27 Respivert Limited Compostos de 1-(3-(tert-butil)-1-(p-tolil)-1h-pirazol-5-il)-3-(4-((2-(fenilamino) pirimidin-4-il)óxi) naftalen-1-il)ureia, seus usos, composição e formulação farmacêutica compreendendo os mesmos
AU2012347350C1 (en) 2011-12-09 2017-01-19 Chiesi Farmaceutici S.P.A. Kinase inhibitors
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
MY167216A (en) 2011-12-09 2018-08-14 Chiesi Farm Spa Kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
KR20160016973A (ko) * 2013-06-06 2016-02-15 키에시 파르마슈티시 엣스. 피. 에이. P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3050525A (en) * 1960-12-14 1962-08-21 John B Bicking Certain derivatives of s-triazolo [4, 3-a]-pyridine
US3754887A (en) * 1969-05-05 1973-08-28 Du Pont Ureidopyrazoles defoliants
US4183854A (en) * 1976-11-10 1980-01-15 John Wyeth & Brother Limited Thiazole compound
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP2627348B2 (ja) * 1990-03-16 1997-07-02 セイコー電子工業株式会社 ラインサーマルプリンタ
WO1996025157A1 (en) 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
AU723730B2 (en) 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
EP0955293B1 (en) * 1996-12-03 2003-03-19 Banyu Pharmaceutical Co., Ltd. Urea derivatives
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
RU2249591C2 (ru) 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
SK157899A3 (en) 1997-05-22 2000-08-14 Searle & Co Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
ATE300299T1 (de) 1997-12-22 2005-08-15 Bayer Pharmaceuticals Corp Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
CA2331878A1 (en) 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
WO2000005999A1 (en) 1998-07-30 2000-02-10 Gulserene Dastur Weather-proof furniture system mainly for outdoor use
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
JP2002534385A (ja) 1999-01-08 2002-10-15 スミスクライン・ビーチャム・コーポレイション 新規化合物
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
AU2001240542A1 (en) * 2000-02-01 2001-08-14 Basf Aktiengesellschaft Heterocyclic compounds and their use as parp inhibitors
US7978329B2 (en) 2000-08-02 2011-07-12 Honeywell International Inc. Portable scattering and fluorescence cytometer
MXPA03008144A (es) 2001-03-09 2003-12-12 Pfizer Prod Inc Nuevos compuestos antiinflamatorios de triazolopiridinas.
CA2453147A1 (en) 2001-07-11 2003-01-23 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
BR0306988A (pt) 2002-01-18 2004-11-23 Pharmacia Corp Piridazinonas substituìdas como inibidores de p38
WO2003068223A1 (en) 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
ES2334990T3 (es) 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
AU2003224257A1 (en) 2002-04-09 2003-10-27 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
MXPA04011638A (es) 2002-06-05 2005-03-07 Pharmacia Corp Derivados de pirazol como inhibidores de la quinasa p38.
JP2005538975A (ja) 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
CA2515190A1 (en) * 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004078116A2 (en) 2003-03-03 2004-09-16 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor

Also Published As

Publication number Publication date
CY1108788T1 (el) 2014-07-02
GT200500218A (es) 2006-03-21
WO2006018718A2 (en) 2006-02-23
IL181047A (en) 2011-06-30
HK1105536A1 (en) 2008-02-15
TNSN07050A1 (fr) 2008-06-02
NL1029726A1 (nl) 2006-02-14
PL1778686T3 (pl) 2009-04-30
SI1778686T1 (sl) 2009-02-28
WO2006018718A3 (en) 2006-05-04
MX2007001759A (es) 2007-04-20
DE602005010714D1 (de) 2008-12-11
EA200700219A1 (ru) 2007-08-31
NO339320B1 (no) 2016-11-28
EA012119B1 (ru) 2009-08-28
US8076356B2 (en) 2011-12-13
MA28798B1 (fr) 2007-08-01
EP1778686B9 (en) 2009-07-08
NZ552868A (en) 2009-07-31
DK1778686T3 (da) 2009-01-12
AR050692A1 (es) 2006-11-15
BRPI0514255A (pt) 2008-06-03
GEP20104973B (en) 2010-04-26
CA2576297C (en) 2011-01-25
CA2576297A1 (en) 2006-02-23
SV2006002193A (es) 2006-03-15
US20060035922A1 (en) 2006-02-16
NL1029726C2 (nl) 2007-08-14
AU2005273612A1 (en) 2006-02-23
PT1778686E (pt) 2008-12-26
AP2326A (en) 2011-11-24
US7511057B2 (en) 2009-03-31
CU23497A3 (es) 2010-03-25
AU2005273612B2 (en) 2010-10-14
EP1778686B1 (en) 2008-10-29
IL181047A0 (en) 2007-07-04
ECSP077232A (es) 2007-03-29
AP2007003905A0 (en) 2007-02-28
ES2314690T3 (es) 2009-03-16
MY140021A (en) 2009-11-30
CR8918A (es) 2007-04-02
HN2005000418A (es) 2009-12-07
EP1778686A2 (en) 2007-05-02
US20090239899A1 (en) 2009-09-24
JP2008509901A (ja) 2008-04-03
JP4084836B2 (ja) 2008-04-30
NO20071242L (no) 2007-05-07
ATE412652T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
HRP20080608T3 (hr) Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze
ES2528451T3 (es) Inhibidores de esfingosina cinasa
AR116109A1 (es) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR096450A1 (es) Compuestos para la modulación de quinasas, y sus indicaciones
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
HRP20020317B1 (hr) Farmaceutski aktivni spojevi
DE602006009080D1 (de) 1-essigsäureindolderivate mit pgd2-antagonistischer wirkung
ATE556058T1 (de) 1-(2h)-isochinolonderivat
AR060316A1 (es) Azaindoles de utilidad como inhibidores de janus quinasas
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
HRP20080477T3 (hr) Aril-piridin derivati kao inhibitori 11-beta-hsd1
AR063101A1 (es) Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2.
CO6220970A2 (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos
AR093504A1 (es) 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos
DOP2006000088A (es) Compuestos utiles en terapia
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
CR10034A (es) Derivados de oxadiazol
EA201100368A1 (ru) Амидные соединения, полезные в терапии
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
RS50642B (sr) Derivati triazolopiridinilsulfanila kao inhibitori p38 map kinaze
AR088246A1 (es) Derivados de etinilo
AR115464A1 (es) Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau
AR097721A1 (es) Derivados de etinilo
AR058329A1 (es) Derivados de pirazolo (4,3-c) piridina sustituidos activos como inhibidores de quinasa, un metodo para su preparacion y composicion farmaceutica